Growing number of incident pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in Latvia: a shifting epidemiological landscape? Data from a national pulmonary hypertension registry

Sablinskis, Kristaps; Sablinskis, Matiss; Lejnieks, Aivars; Skride, Andris

doi:10.1016/j.ejim.2018.09.017

Cited by 7 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the profile of the population, the epidemiological characteristics found in this study are similar to those of developed countries. The mean age at diagnosis was similar to that found in Latvia, where the mean age at diagnosis of PAH and CTEPH was 63.7 ± 18.0 and 71.4 ± 8.2 years, respectively 3 . A European registry that analyzed the prevalence of PAH in the population also found that 63% of the sample was composed of older adults, with a mean age of 65 years 4 .…”

Section: Discussionsupporting

confidence: 81%

“…A Brazilian study with PAH 5 found a 2.3:1 ratio between women and men, which is similar to international data, which shows that women represent 69.3% of patients with PAH 7 . A study that evaluated both etiologies of PH (PAH and CTEPH) also showed a prevalence of females in both groups: 83% in PAH and 74% in CTEPH 3 .…”

Section: Discussionmentioning

confidence: 91%

“…Studies describing the characteristics of the population with CTEPH are rare in the literature 3 . In Brazil, this is the first study with this objective, which demonstrates the need for complementary work with large population samples.…”

Section: Discussionmentioning

confidence: 99%

“…Group PAH (Group 1) and CTEPH (Group 4) are both rare and often underdiagnosed. According to European data, the estimated incidence and prevalence are, respectively, from 0.9 to 3.7 and from 7 to 52 cases per million inhabitants for PAH and from 0.3 to 5.7 and from 3 to 19 cases per million inhabitants for CTEPH 3 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Perfil clínico-hemodinâmico de pacientes com hipertensão arterial pulmonar e hipertensão pulmonar tromboembólica crônica de um hospital terciário de São Paulo

Santos

Alves

Vitório

et al. 2022

Rev. Med. (São Paulo)

View full text Add to dashboard Cite

Objetivo. Descrever as características clínicas e hemodinâmicas dos pacientes com Hipertensão Arterial Pulmonar (HAP) e Hipertensão Pulmonar Tromboembólica Crônica (HPTEC) atendidos no Hospital do Servidor Público Estadual de São Paulo (HSPE). Métodos. Foram revisados os prontuários dos pacientes em seguimento no ambulatório de Circulação Pulmonar do HSPE em acompanhamento entre 2012 e 2019. Hipertensão pulmonar (HP) foi confirmada por cateterismo cardíaco direito e o diagnóstico final de HAP ou HPTEC foi confirmado após avaliação especializada. Resultados. Foram avaliados 46 casos de HP, sendo 31 de HAP e 15 de HPTEC. A média de idade foi de 67,5 (± 10,5) anos, com uma frequência de participantes com idade maior que 60 anos de 73,9%. Houve predomínio do sexo feminino (69,6%). A mediana do tempo de dispneia até o diagnóstico foi de 2 anos. A principal etiologia da HAP foi a esclerose sistêmica e não houve casos de esquistossomose na população estudada. Havia sinais de disfunção do ventrículo direito no momento do diagnóstico em 73,3% dos casos. Entre os pacientes com HPTEC, 46,7% desconheciam evento tromboembólico prévio. Conclusões. Este estudo abordou uma população predominantemente idosa com diagnóstico de HP, destacando as características de dois subtipos da doença. Há necessidade de novos estudos para melhorar o entendimento sobre HP na população brasileira, em especial sobre os portadores de HPTEC.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Perfil clínico-hemodinâmico de pacientes com hipertensão arterial pulmonar e hipertensão pulmonar tromboembólica crônica de um hospital terciário de São Paulo

Santos

Alves

Vitório

et al. 2022

Rev. Med. (São Paulo)

View full text Add to dashboard Cite

show abstract

“…The group of CTEPH patients was well characterized in a large prospective international registry which enrolled patients between February 2007 and January 2009. 7 As the phenotype of CTEPH patients may be population dependent, 8 several national reports as summarized in Table 1 7 , 9 – 29 were of added value. Most of them, however, recruited patients before the marketing authorization of riociguat by the European Medicines Agency through the European Union (27/03/2014), and before the first experience with balloon pulmonary angioplasty (BPA) outside of Japan.…”

Section: Introductionmentioning

confidence: 99%

Characteristics and outcomes of patients with chronic thromboembolic pulmonary hypertension in the era of modern therapeutic approaches: data from the Polish multicenter registry (BNP-PL)

Kopeć

Dzikowska-Diduch

Mroczek

et al. 2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Background: Significant achievements in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) have provided effective therapeutic options for most patients. However, the true impact of the changed landscape of CTEPH therapies on patients’ management and outcomes is poorly known. We aimed to characterize the incidence, clinical characteristics, and outcomes of CTEPH patients in the modern era of CTEPH therapies. Methods: We analyzed the data of CTEPH adults enrolled in the prospective multicenter registry. Results: We enrolled 516 patients aged 63.8 ± 15.4 years. The incidence rate of CTEPH was 3.96 per million adults per year. The group was burdened with several comorbidities. New oral anticoagulants ( n = 301; 58.3%) were preferred over vitamin K antagonists ( n = 159; 30.8%). Pulmonary endarterectomy (PEA) was performed in 120 (23.3%) patients and balloon pulmonary angioplasty (BPA) in 258 (50%) patients. PEA was pretreated with targeted pharmacotherapy in 19 (15.8%) patients, and BPA in 124 (48.1%) patients. Persistent CTEPH was present in 46% of PEA patients and in 65% of patients after completion of BPA. Persistent CTEPH after PEA was treated with targeted pharmacotherapy in 72% and with BPA in 27.7% of patients. At a mean time period of 14.3 ± 5.8 months, 26 patients had died. The use of PEA or BPA was associated with better survival than the use of solely medical treatment. Conclusions: The modern population of CTEPH patients comprises mostly elderly people significantly burdened with comorbid conditions. This calls for treatment decisions that are tailored individually for every patient. The combination of two or three methods is currently a frequent approach in the treatment of CTEPH. Clinical Trial Registration: clinicaltrials.gov/ct2/show/NCT03959748

show abstract

Inoperable chronic thromboembolic pulmonary hypertension: Evolution of prognosis over 10 years of new emerging therapies

Staal,

Hendriks,

van Thor

et al. 2024

Pulm. circ.

View full text Add to dashboard Cite

show abstract

Growing number of incident pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in Latvia: a shifting epidemiological landscape? Data from a national pulmonary hypertension registry

Cited by 7 publications

References 9 publications

Perfil clínico-hemodinâmico de pacientes com hipertensão arterial pulmonar e hipertensão pulmonar tromboembólica crônica de um hospital terciário de São Paulo

Perfil clínico-hemodinâmico de pacientes com hipertensão arterial pulmonar e hipertensão pulmonar tromboembólica crônica de um hospital terciário de São Paulo

Characteristics and outcomes of patients with chronic thromboembolic pulmonary hypertension in the era of modern therapeutic approaches: data from the Polish multicenter registry (BNP-PL)

Inoperable chronic thromboembolic pulmonary hypertension: Evolution of prognosis over 10 years of new emerging therapies

Contact Info

Product

Resources

About